OpenEvidence

- 21/02/2025
- Series A
- Undisclosed Amount
Launched during the Mayo Clinic Platform Accelerate program and featured by the New England Journal of Medicine AI, OpenEvidence is the world’s leading medical AI.
- Industry Software Development
- Website https://www.openevidence.com/
- LinkedIn https://www.linkedin.com/company/openevidence/
Related People
Daniel NadlerFounder

While still a Ph.D. student at Harvard, Nadler founded Kensho Technologies, an artificial intelligence company that in 2018 became the most valuable privately owned artificial intelligence company in history (according to Forbes) when it was acquired by S&P Global (NYSE: SPGI) for $700 million.
In 2021 Nadler founded OpenEvidence, a medical AI company whose eponymous medical search engine is used by doctors for clinical decision support. In 2023 OpenEvidence was valued at $425 million, according to Forbes. As of 2024, OpenEvidence is used by more than 250,000 doctors in the United States.
Outside of technology, Nadler is an award-winning poet and visual artist; his debut collection of poetry, Lacunae, was published Farrar, Straus and Giroux in 2016 and was named by NPR as one of the Best Books of the Year.
In 2020, Nadler was invited to serve on the Digital Art Committee of the Whitney Museum, where he continues to play an active leadership role. In 2021 Nadler was elected to the Board of Directors of the Museum of Modern Art (MoMA) PS1.